Dr. Albert Friesen reports

MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 9, 2024 CALL AT 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023

Medicure Inc. will present the 2023 year-end financial results on a conference call on April 9, 2024, at 8:30 a.m. ET. The 2023 year-end financials will be filed after closing on April 8, 2024.

Conference call info:

Topic:  Medicure's 2023 year-end results

Call date:  Tuesday, April 9, 2024

Time:  7:30 a.m. CT (8:30 a.m. ET)

Toll-free:  1-888-506-0062

International:  1-973-528-0011

Participant access code:  444626

Webcast: This conference call will be webcast live over the Internet.

You may request international country-specific access information by e-mailing the company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the company's website.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the company is the marketing and distribution of Aggrastat (tirofiban hydrochloride) injection and Zypitamag (pitavastatin) tablets in the United States, where they are sold through the company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc., a pharmacy located in North Carolina that offers an extended supply drug program serving all 50 states, Washington, D.C., and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers.

We seek Safe Harbor.